Chronic treatment with small does of cabergoline prevents dopa-induced dyskinesias in Parkinsonian monkeys

Movement Disorders

Volumn 18, Issue 12, 2003, Pages 1436-1441

  Bélanger, Nancy ^a   Grégoire, Laurent ^a   Tahar, Abdallah Hadj ^a   Bédard, Paul J ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cabergoline; D2 receptor; Levodopa induced dyskinesias; MPTP treated monkeys; Parkinson's disease

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEVODOPA; POSTSYNAPTIC RECEPTOR;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; FEMALE; LOCOMOTION; LOW DRUG DOSE; MONKEY; NERVE CELL STIMULATION; NERVE TRACT; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; ERGOLINES; FEMALE; LOCOMOTION; MACACA FASCICULARIS; PARKINSON DISEASE; POSTURE;

EID: 0345770367     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10589     Document Type: Article

References (64)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden C, Fahn S, editors. Movements disorders. London: Butterworth Scientific; 1982. p 96-122.
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with levodopa. N Engl J Med 1969;280: 337-345.
3. Yhar MD, Duvoisin RC, Schear MJ. Treatment of parkinsonism with levodopa. Arch Neurol 1969;280:343-354.
4. Barbeau A. Levodopa therapy in Parkinson's disease-a critical review of nine years experience. Can Med Assoc J 1969;101:791-800.
5. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40.
6. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa in Parkinson's disease. Q J Med 1980;49:283-293.
7. Barbeau A. High-level levodopa therapy in severely akinetic parkinsonism patients: twelve years later. In: Rinne VK, Klinger M, Stamm G, editors. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier; 1980. p 229-239.
8. Nutt JG. Levodopa-induced dyskinesias: review, observations and speculations. Neurology 1990;40:340-345.
9. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
10. Nutt JG. Levodopa-induced dyskinesias. Neurology 1990;40:340-345.
11. Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999;52:120-125.
12. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. I. Ann Neurol 1988;24:366-371.
13. Post RM. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci 1980;26:1275-1286.
14. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(Suppl.):S15-S18.
15. Blanchet PJ, Gomez-Mancilla B, DiPaolo T, Bedard PJ. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fundam Clin Pharmacol 1995;9:434-442.
16. Nutt JG, Carter JH, Van Houten L, Woodward WR. Short and long duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997;42:349-355.
17. Crossman AR. A hypothesis on the pathophysiological mechanism that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implication for future strategies in treatment. Mov Disord 1990;5:100-108.
18. 11C]raclopride displacement and PET. Neurology 1996;46:1430-1436.
19. 2 receptor? Mov Disord 1997;12:112.
20. Torstenson R, Hartvig P, Langstorn B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997;41:334-340.
21. Schwarcz R, Creese I, Coyle JT, Snyder SH. Dopamine receptors localized on cerebral cortical afferents to rats corpus striatum. Nature 1978;271:766-768.
22. Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci U S A 1993;90:9576-9580.
23. Flores-Hernandes J, Cepeda C, Fienberg AA, Greengard P, Levine MS. Multiple pathways are involved in the enhancement of NMDA responses by activation of dopamine D1 receptors in neostriatal neurons. Soc Neurosci Abstr 1999;25:1156.
24. Levine MS, Li Z, Cepeda C, Cromwell HC, Altemus KL. Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse 1996;24:65-78.
25. 2 dopamine receptors are located on striatal glutamatergic nerves terminals. J Pharmacol Exp Ther 1988;247:680-684.
26. 2 receptors mediating inhibition of release. J Pharmacol Exp Ther 1989;251:1142-1146.
27. Mitchell PR, Doggett NS. Modulation of striatal [3H]-glutamic acid release by dopaminergic drugs. Life Sci 1980;26:2073-2081.
28. Kornhuber J, Kornhuber ME. Presynaptic dopaminergic modula tion of cortical input to the striatum. Life Sci 1986;39:674-699.
29. Rowlands GF, Roberts PJ. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminals in vitro. Eur J Pharmacol 1980;62:241-242.
30. Yamamoto BK, Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 1992;58:1736-1742.
31. 2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
32. Blanchet PJ, Grondin R, Bedard PJ, Shiosaki K, Britton DR. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol 1996;309:13-20.
33. 2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 1996;735:298-306.
34. 2 dopaminergic agonists on rotational behavior in supersensitive mice. J Pharmacol Exp Ther 1989;249:507-516.
35. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs Suppl 1998;1:1-9.
36. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Drugs Suppl 1998;1:10-16.
37. Hadj Tahar A, Gregoire L, Bangassoro E, Bedard PJ. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000;23:195-202.
38. 3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990;187:399-408.
39. Fahn S, Cote LJ, Snider SR, Barrett RE, Isgreen WP. The role of bromocriptine in the treatment of parkinsonism. Neurology 1979; 29:1077-1083.
40. Lang AE, Quinn N, Bcat S, Marsden CD, Parkes JD. Pergolide in late-stage Parkinson's disease. Ann Neurol 1982;12:243-247.
41. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzhy RL, Waters CH, Muenter MD, Adler CH, Morris JL. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-1065.
42. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mooradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39:7-10.
43. Goldstein M, Harada. K, Meller E, Schalling M, Hokfelt T. Dopamine autoreceptors. Biochemical, pharmacological, and morphological studies. Ann NY Acad Sci 1990;604:169-175.
44. Hadj Tahar A, Gregoire L, Darre A, Belanger N, Meltzer L, Bedard PJ. Selective glutamate antagonist prevents levodopa-induced dyskinesias in MPTP monkeys. Soc Neurosci Abstr 2001.
45. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1996; 55(Suppl.):17-22.
46. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1995;39:336-339.
47. Gimenez-Roldan S, Tolosa E, Burguera JA. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997;20:67-76.
48. ++-channels involved in neostriatal glutamatergic transmission. Brain Res Bull 1998;45:521-524.
49. Lovinger DM, Merritt A, Reyes D. Involvement of N- and non-N-type calcium channels in synaptic transmission at corticostriatal synapses. Neuroscience 1994;62:31-40.
50. Berkowicz DA, Trombley PQ. Dopaminergic modulation at the olfactory nerve synapse. Brain Res 2000;855:90-99.
51. 2-like receptors inhibit excitatory transmission into rat ventral tegmental dopaminergic neurons. J Physiol (Lond) 2000;523:163-173.
52. Miyazaki T, Lacey MG. Presynaptic inhibition by dopamine of a discrete component of GABA release in rat substantia nigra pars reticulata. J Physiol (Lond) 1998;513:805-817.
53. Shoji Y, Delfs J, Williams JT. Presynaptic inhibition of GABA (B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 1999;19:2347-2355.
54. Calabresi P, Mercuri N, Sancesario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Brain 1993;116: 433-452.
55. 2 dopamine receptor-deficient mice. J Neurophysiol 2001;85:659-670.
56. Cepeda C, Walsh JP, Hull CD, Howard SG, Buchwald NA, Levine MS. Dye-coupling in the neostriatum of the rat. I. Modulation by dopamine-depletion lesions. Synapse 1989;4:229-237.
57. Galarraga E, Bargas J, Martinez-Fong D, Aceves J. Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons. Neurosci Lett 1987;81:351-355.
58. Schultz W. Depletion of dopamine in the striatum as an experimental model of parkinsonism: direct effects and adaptive mechanisms. Prog Neurobiol 1982;18:121-166.
59. Grondin R, Bedard P.J. Cabergoline: a promising agent for the treatment of Parkinson's disease. CNS Drugs Rev 1996;1:214-225.
60. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:68-72.
61. 2 agonist LY-171555 in the MPTP-treated marmoset. Neurosci Lett 1988;93:275-280.
62. Seale TW, McLanahan K, Jonhson P, Carney JM, Rennert OM. Systematic comparison of apomorphine-induced behavioral changes in two mouse strains with inherited differences in brain dopamine receptors. Pharmacol Biochem Behav 1984;21:237-244.
63. Rinnes UK, Bracco F, Chouza C. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
64. Rinnes UK, Bracco F, Chouza C. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs 1998;55:23-30.